| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Turimycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis. Specifically, it binds to the 23S rRNA, blocking the peptidyl transferase activity and preventing the elongation of the polypeptide chain. This bacteriostatic action inhibits bacterial growth and replication.
|
|---|---|
| ln Vitro |
In vitro, turimycin exhibits potent antibacterial activity against a wide range of Gram-positive bacteria, including Staphylococcus aureus, Streptococcus spp., and some Gram-negative bacteria. Its minimum inhibitory concentration (MIC) for susceptible strains is typically in the low microgram per milliliter range. It is also active against some mycoplasmas.
|
| ln Vivo |
In vivo, turimycin is used in veterinary medicine to treat respiratory and enteric infections in poultry, swine, and cattle. It is effective against infections caused by susceptible Gram-positive bacteria. It is often administered in feed or water for the treatment of disease outbreaks. It is also used as a growth promoter in some countries.
|
| Enzyme Assay |
The in vitro antibacterial activity of turimycin is assessed using standard broth dilution or agar dilution methods. The minimum inhibitory concentration (MIC) is determined by culturing bacteria in the presence of serial dilutions of the compound. The lowest concentration that inhibits visible bacterial growth after 18-24 hours of incubation is recorded as the MIC.
|
| Cell Assay |
In vitro cellular assays for turimycin are not typically performed, as it is an antibacterial agent that acts on bacterial ribosomes. Its activity is assessed using bacterial cultures. The effect on eukaryotic cells is not relevant for its antibacterial action, though its cytotoxicity can be assessed for safety purposes.
|
| Animal Protocol |
In vivo animal experiments for turimycin are conducted in animal models of bacterial infection. Animals are infected with a pathogenic bacterium, and turimycin is administered (e.g., orally, in feed, or by injection). The survival rate, reduction in bacterial load, and resolution of clinical signs are measured to assess its therapeutic efficacy.
|
| ADME/Pharmacokinetics |
Turimycin is absorbed after oral administration, though the extent of absorption may vary depending on the species and formulation. It is distributed to various tissues and is primarily eliminated in the feces. Its half-life is relatively short, typically a few hours. Its pharmacokinetics have been studied in various animal species for the purpose of establishing dosage regimens.
|
| Toxicity/Toxicokinetics |
Turimycin is generally well-tolerated in animals at therapeutic doses. Common side effects are mild and may include gastrointestinal disturbances such as diarrhea. Allergic reactions are rare. It should be used with caution in animals with hepatic or renal impairment. Withdrawal periods are required for food-producing animals to ensure that residues do not enter the human food chain.
|
| References | |
| Additional Infomation |
Leucomycin V is a macrolide antibiotic produced by Streptomyces kitasatoensis, exhibiting antibacterial activity against a variety of pathogens. It is a bacterial metabolite. It is both a Leucomycin class antibiotic and a macrolide antibiotic. Leucomycin V has been reported to be present in both Streptomyces kitasatoensis and Streptomyces hygroscopicus, and relevant data are available. Leucomycin V is a macrolide antibiotic produced by Streptomyces kitasatoensis. This drug has antibacterial activity against a variety of pathogens.
Turimycin is a veterinary antibiotic that is not approved for use in humans. It is used in the treatment of bacterial infections in livestock and poultry. Its use as a growth promoter has been phased out in many countries due to concerns about antibiotic resistance. It is a member of the macrolide class of antibiotics, which are important in both human and veterinary medicine. |
| Molecular Formula |
C40H67NO14
|
|---|---|
| Molecular Weight |
785.96
|
| Exact Mass |
785.456
|
| CAS # |
1392-21-8
|
| PubChem CID |
5282189
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
874.7±65.0 °C at 760 mmHg
|
| Flash Point |
482.8±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
3.35
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
49
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)O
|
| InChi Key |
XYJOGTQLTFNMQG-KJHBSLKPSA-N
|
| InChi Code |
InChI=1S/C35H59NO13/c1-19-16-23(14-15-37)31(32(44-8)25(39)17-26(40)45-20(2)12-10-9-11-13-24(19)38)49-34-29(41)28(36(6)7)30(21(3)47-34)48-27-18-35(5,43)33(42)22(4)46-27/h9-11,13,15,19-25,27-34,38-39,41-43H,12,14,16-18H2,1-8H3/b10-9+,13-11+/t19-,20-,21-,22+,23+,24+,25-,27+,28-,29-,30-,31+,32+,33+,34+,35-/m1/s1
|
| Chemical Name |
2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[(2S,3R,4R,5S,6R)-5-[(2S,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.75 mg/mL (Infinity mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2723 mL | 6.3616 mL | 12.7233 mL | |
| 5 mM | 0.2545 mL | 1.2723 mL | 2.5447 mL | |
| 10 mM | 0.1272 mL | 0.6362 mL | 1.2723 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
